https://orcid.org/0000-0002-5457-9420
References
- Akel T, Bekheit S. Loperamide cardiotoxicity: “A brief review”. Ann Noninvasive Electrocardiol. 2018 Mar;23(2):e12505.
- Sobczak M, Sałaga M, Storr MA, et al. Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives. J Gastroenterol. 2014 Jan 1;49(1):24–45.
- Kang J, Compton DR, Vaz RJ, et al. Proarrhythmic mechanisms of the common anti-diarrheal medication loperamide: revelations from the opioid abuse epidemic. Naunyn-Schmiedeberg’s Arch Pharmacol. 2016 Oct 1;389(10):1133–1137.
- Miller H, Panahi L, Tapia D, et al. Loperamide misuse and abuse. J Am Pharm Assoc. 2017 Mar 1;57(2):S45–50.
- Wu PE, Juurlink DN. Clinical review: loperamide toxicity. Ann Emerg Med. 2017 Aug 1;70(2):245–252.
- Marraffa JM, Holland MG, Sullivan RW, et al. Cardiac conduction disturbance after loperamide abuse. Clin Toxicol. 2014 Nov 1;52(9):952–957.
- Vaz RJ, Kang J, Luo Y, et al. Molecular determinants of loperamide and N-desmethyl loperamide binding in the hERG cardiac K+ channel. Bioorg Med Chem Lett. 2018 Feb 1;28(3):446–451.
- Klein MG, Haigney MC, Mehler PS, et al. Potent inhibition of hERG channels by the over-the-counter antidiarrheal agent loperamide. JACC: Clin Electrophys. 2016 Dec 1; 2(7):784–789.
- Vaughn P, Solik MM, Bagga S, et al. Electrocardiographic abnormalities, malignant ventricular arrhythmias, and cardiomyopathy associated with loperamide abuse. J Cardiovasc Electrophysiol. 2016 Oct;27(10):1230–1233.
- Eggleston W, Nacca N, Marraffa JM. Loperamide toxicokinetics: serum concentrations in the overdose setting. Clin Toxicol. 2015 May 28;53(5):495–496.